Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Predictive value of in‑vitro drug sensitivity testing on patient-derived tumoroids in metastatic pancreatic cancer
2018-003112-53Phase 2Completed
- Sponsor
- Vejle Hospital
- Start
- Aug 2018
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of oxaliplatin, capecitabine, irinotecan, fluorouracil, gemcitabine and 5 more in pancreatic cancer (PC), sponsored by Vejle Hospital. Primary endpoint: Predictive value of in-vitro drug sensitivity testing for first-line chemotherapy response. Started Aug 2018; status: completed.
02
Drugs
oxaliplatincapecitabineirinotecanfluorouracilgemcitabine
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on 2018-003112-53.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003112-53.